Find a Clinical Trial

Filter

Showing 1 - 10 out of 17

OCEANIC-STROKE

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA

Ischemic stroke, Transient ischemic attack

All genders

18+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)

A phase 3 randomized, open-label study of OP-1250 monotherapy vs standard of care for the treatment of ER+, HER2– advanced or metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy (OPERA-01)

Breast cancer, Locally advanced and metastatic breast cancer

All genders

18+

Recruiting now

Cancer Center

Tufts Medical Center

Learn more

SUMMIT MAX

A Prospective, Randomized, Controlled, Interventional Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPoint® Reperfusion System for Aspiration Embolectomy in Acute Ischemic Stroke Patients

Stroke

All genders

18-85

Recruiting now

Department of Neurosurgery

Tufts Medical Center

Learn more

AbbVie EAISE

A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke

Stroke

All genders

30-80

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

PFO-PAS

Amplatzer PFO Occluder Post Approval Study (PFO PAS)

Stroke

All genders

18-60

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

ASPIRE

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Intracerebral hemorrhage

All genders

18+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

ARCADIA

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

Stroke

All genders

45+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

Breast Cancer Database

Breast cancer

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

All genders

18+

Recruiting now

Cancer Center

Tufts Medical Center

Learn more

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

DESTINY BREAST - RESPOND: A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer (D9673R00025)

Breast cancer

All genders

16+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A phase 3 randomized, open-label study of OP-1250 monotherapy vs standard of care for the treatment of ER+, HER2– advanced or metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy (OPERA-01)

A Prospective, Randomized, Controlled, Interventional Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPoint® Reperfusion System for Aspiration Embolectomy in Acute Ischemic Stroke Patients

A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke

Amplatzer PFO Occluder Post Approval Study (PFO PAS)

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

Breast Cancer Database

DESTINY BREAST - RESPOND: A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer (D9673R00025)